CPI-1205
- Generic Name
- CPI-1205
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H33F3N4O3
- CAS Number
- 1621862-70-1
- Unique Ingredient Identifier
- 455J2479FY
- Background
Potent and selective histone methyltransferase EZH2 inhibitor.
- Associated Conditions
- -
- Associated Therapies
- -
ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Constellation Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03525795
- Locations
- ๐บ๐ธ
START Midwest, Grand Rapids, Michigan, United States
๐บ๐ธSouth Texas Oncology & Hematology, San Antonio, Texas, United States
๐บ๐ธThe University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- Constellation Pharmaceuticals
- Target Recruit Count
- 242
- Registration Number
- NCT03480646
- Locations
- ๐บ๐ธ
University of Illinois Hospital and Health Systems, Chicago, Illinois, United States
๐บ๐ธJohn Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
- First Posted Date
- 2015-03-23
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Constellation Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT02395601
- Locations
- ๐บ๐ธ
John Theurer Cancer Center, Hackensack, New Jersey, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธSarah Cannon Research Institute, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.